Premaitha Health PLC Premaitha to attend key conferences in Middle East
06 February 2018 - 6:00PM
RNS Non-Regulatory
TIDMNIPT
Premaitha Health PLC
06 February 2018
Premaitha Health plc
("Premaitha" or the "Company")
Premaitha raises awareness of the IONA(R) test
at key conferences in the Middle East
Manchester, UK - 6 February 2018: Premaitha Health plc (AIM:
NIPT), a leading international molecular diagnostics group focused
on prenatal testing, announces it will be participating in key
conferences in the Middle East to further raise the profile of the
IONA(R) test across this region.
Medlab Dubai
Medlab is one of the largest medical laboratory exhibitions in
the world and is held in Dubai from 5 to 8 February 2018. Premaitha
is hosting an exhibition stand at the event and showcasing the
IONA(R) test to the Medlab attendees, comprising both existing and
prospective customers and distributors across the Middle East.
For further details, please visit:
www.medlabme.com/en/home.html
Egyptian Fetal Medicine Foundation, 4(th) Annual Conference
The Egyptian Fetal Medicine Foundation conference ("EFMF") will
be held in Cairo, Egypt on 8 and 9 February 2018. The event
attracts leading clinicians from across Egypt and the Middle
East.
Premaitha will host an exhibition stand at the event and the
Company's Head of Operations, Dr Sean Sales, will be giving a
presentation to delegates providing a clinical and technical
overview of non-invasive prenatal screening ("NIPT").
Through its participation at the event, Premaitha aims to raise
awareness of the IONA(R) test and engage and educate leading fetal
medicine clinicians on the benefits of adopting NIPT.
For further details, please visit: efmf-eg.org/index.php
Premaitha's IONA(R) test estimates the risk of a fetus being
affected with Down's syndrome or other genetic conditions. The test
is performed on a maternal blood sample, containing traces of fetal
DNA, which is then analysed using next generation DNA sequencing
technology. The test is highly accurate and significantly reduces
the number of women who are unnecessarily subjected to risky,
invasive follow up procedures to diagnose Down's syndrome and other
genetic conditions.
Dr Stephen Little, CEO of Premaitha Health, commented: "We
continue to see increasing traction across the Middle East for the
IONA(R) test. These key industry events will enable us to further
raise awareness of both the IONA(R) test and the benefits of
adopting NIPT, with a view to further enhancing our distribution
networks in the region."
For more information, please contact:
Tel: +44 (0)161
Premaitha Health PLC 667 1053
Dr Stephen Little, Chief Executive
Officer
Barry Hextall, Chief Financial Officer
Joanne Cross, Head of Marketing
investors@premaitha.com
Cairn Financial Advisers LLP (NOMAD) Tel: +44 (0)20
Liam Murray / James Caithie 7213 0880
Tel: +44 (0)20
finnCap (Broker) 7220 0500
Adrian Hargrave / Scott Mathieson
(Corporate Finance)
Andrew Burdis / Abigail Wayne (Corporate
Broking)
Tel: +44 (0)20
Vigo Communications 7830 9700
Ben Simons / Fiona Henson / Antonia
Pollock
premaitha@vigocomms.com
About Premaitha
Premaitha is an international molecular diagnostics group which
uses the latest advances in DNA analysis technology to develop
safer, faster and regulatory approved genetic screening tests. The
Group's primary focus is on non-invasive prenatal tests (NIPT) for
pregnant women - an emerging, multi-billion dollar global
market.
Premaitha's IONA(R) test was launched in 2015 as the first
CE-IVD NIPT test in Europe. It enables laboratories and healthcare
practitioners to offer a complete CE-marked NIPT system in-house.
The IONA(R) test is performed on a maternal blood sample - which
contains traces of fetal DNA - and estimates the risk of a fetus
being affected with Down's syndrome or other genetic
conditions.
Unlike existing prenatal screening methods, due to its high
level of accuracy, the IONA(R) test can significantly reduce the
number of women subjected to unnecessary invasive follow up
diagnostic procedures, such as amniocentesis, which are costly,
resource intensive and carry a risk of miscarriage.
In March 2017, Premaitha acquired Yourgene Bioscience, a
specialist next generation sequencing and bioinformatics company
based in Taiwan, with its own NIPT screening test that operates on
the same Thermo Fisher next-generation sequencing platform as
Premaitha's IONA(R) test. Yourgene brings significant benefits to
the Group through expanded market access in Asia - the world's
fastest growing NIPT market - as well as opportunities for
cross-selling and the ability to jointly develop expanded test
content both within NIPT and beyond.
Premaitha is headquartered in Manchester, England, with Yourgene
offices in Taipei and Singapore. Its shares trade on the AIM market
of the London Stock Exchange (AIM: NIPT). For further information,
please visit www.premaitha.com. Follow us on twitter
@PremaithaHealth.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRATAMFTMBJMBAP
(END) Dow Jones Newswires
February 06, 2018 02:00 ET (07:00 GMT)
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2023 to May 2024